Minneapolis R&D Tax Credit and Its Benefits to Companies

R&D Tax Credits for Minneapolis, Minnesota Businesses

Minneapolis, Minnesota, is a hub for industries such as healthcare, education, technology, and finance. Top companies in the city include UnitedHealth Group, a leading healthcare provider; the University of Minnesota, a key educational institution; Target Corporation, a prominent retail company; U.S. Bancorp, a major financial services provider; and General Mills, a major food production company. The Research and Development (R&D) Tax Credit can help these industries reduce their tax liabilities, foster innovation, and enhance business performance.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 14870 Granada Avenue, Apple Valley, Minnesota is less than 20 miles away from Minneapolis and provides R&D tax credit consulting and advisory services to Minneapolis and the surrounding areas such as: Saint Paul, Bloomington, Brooklyn Park, Plymouth and Woodbury.

If you have any questions or need further assistance, please call or email our local Minnesota Partner on (952) 236-4344.
Feel free to book a quick teleconference with one of our Minnesota R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Minneapolis, Minnesota Patent of the Year – 2024/2025

Nanocopoeia LLC has been awarded the 2024/2025 Patent of the Year for innovation in drug delivery systems. Their invention, detailed in U.S. Patent No. 12016861, titled ‘Amorphous nilotinib microparticles and uses thereof’, introduces a new formulation method to enhance how cancer drugs work in the body.

This patent covers a process for creating amorphous microparticles of nilotinib, a drug used to treat certain types of leukemia. By using an amorphous form rather than a crystalline one, Nanocopoeia improves the drug’s solubility and bioavailability, making it more effective at lower doses.

The technology relies on precise control of particle structure at the microscopic level. The result is a formulation that dissolves more easily in the bloodstream, delivering more consistent and targeted therapeutic results. This advancement could reduce side effects and improve outcomes for patients.

With this patent, Nanocopoeia takes a major step toward safer, more efficient cancer treatments. The method can potentially be adapted for other drugs that suffer from poor solubility, opening the door for broader medical use. This approach aligns with a growing push for personalized, efficient therapies that are easier for patients to tolerate.

Nanocopoeia’s invention highlights how materials science can transform pharmaceutical delivery. It’s a leap forward for both oncology care and the future of nanomedicine.